|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.59 USD | -5.92% |
|
-5.92% | -42.60% |
| Mar. 18 | Transcript : Biofrontera Inc., Q4 2023 Earnings Call, Mar 18, 2024 | |
| Mar. 15 | Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Biofrontera Inc. announced the appointment of Kevin D. Weber to its Board of Directors, expanding Board membership to five Directors. Mr. Weber is an experienced pharmaceutical executive who brings to Biofrontera more than 30 years of executive and commercialization experience with a particular expertise in product marketing. He is currently a Principal at Skysis.
Mr. Weber previously served on the Boards of Directors of the American Academy of Pain Medicine Foundation.
| 1st Jan change | Capi. | |
|---|---|---|
| -42.60% | 8.6M | |
| +25.95% | 653B | |
| +27.00% | 556B | |
| -6.72% | 354B | |
| +20.30% | 331B | |
| +2.68% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -5.90% | 144B |
BIOFRONTERA INC. 
